Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398710 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00398710 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 37 participants.
The verdict
NCT00398710, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a two-stage phase II study design to permit early stopping of the trial if there is strong evidence that the study regimen is inactive. In addition, it will assess toxicity of this drug in patients with WM. Patients will receive perifosine 150 mg qhs daily. Patients will be assessed by serum immunoelectrophoresis and IgM level at least every 4 weeks.
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398710
The ClinicalTrials.gov registry entry for NCT00398710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00398710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398710 about?
NCT00398710 is a clinical study titled "A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia". This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a two-stage phase II study design to permit early stopping of the trial if there is strong evidence that the study regimen ...
What is the current status of trial NCT00398710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2006-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00398710?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00398710?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.